SINT Stock Forecast & Price Target

SINTX Technologies is attractive because it is transforming from a silicon nitride biomaterials platform into a commercial orthopedic and biomaterials company, with differentiated properties such as antimicrobial activity, osteoconductivity, radiolucency, and implant history supporting broader adoption. The October 2025 FDA 510(k) clearance, the March 2026 first-in-human procedure, and the June 2025 SiNAPTIC asset acquisition create a clear clinical and commercial pathway, while the December 2025 Evonik agreement broadens access to patient-specific SiN/PEEK manufacturing. Although 1Q26 revenue was only $0.38M, it increased 3% year over year and continuing operations showed stronger growth, including 46% higher remaining revenue and 32% higher product revenue, reinforcing early traction in a large opportunity.

SINTX Technologies is facing a weak fundamental profile, as Q2 2026 revenue of $0.5 million remained modest while the company still posted a $3.6 million net loss, or $(0.75) per share, highlighting a large gap between sales and operating costs. The lack of Q2 guidance further underscores limited near-term visibility, and the business remains exposed to balance sheet and liquidity risk, which can constrain development, commercialization, and execution. In addition, management faces meaningful uncertainty around clinical safety and efficacy, regulatory approvals, reimbursement, and competitive pressures, all of which make sustainable value creation difficult.